

Amendments to the Claims:

1-57. (canceled)

58. (currently amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

- (a) — ~~a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~
 - (b) — ~~a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~
 - (c) — ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352);~~
 - (d) — ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~
 - [[~~(e)]~~] the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);
 - (f) — ~~the full length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~
 - (g) — ~~the full length coding sequence of the cDNA deposited under ATCC accession number 209905~~
- wherein the encoded polypeptide has fetal hemoglobin inducing activity.

59. (currently amended) The isolated nucleic acid of Claim 58 having at least 85% nucleic acid sequence identity to:

- (a) — ~~a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~
- (b) — ~~a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

- (c) — a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352);
- (d) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- [(e)] the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);
- (f) — the full length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or
- (g) — the full length coding sequence of the cDNA deposited under ATCC accession number 209905

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

60. (currently amended) The isolated nucleic acid of Claim 58 having at least 90% nucleic acid sequence identity to:

- (a) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);
- (b) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- (c) — a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352);
- (d) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- [(e)] the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);
- (f) — the full length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or

(g) — the full length coding sequence of the cDNA deposited under ATCC accession number 209905

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

61. (currently amended) The isolated nucleic acid of Claim 58 having at least 95% nucleic acid sequence identity to:

(a) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);

(b) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;

(c) — a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352);

(d) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;

[(e)] — the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);

(f) — the full length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or

(g) — the full length coding sequence of the cDNA deposited under ATCC accession number 209905

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

62. (currently amended) The isolated nucleic acid of Claim 58 having at least 99% nucleic acid sequence identity to:

(a) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);

(b) — a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;

- (c) — a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352);
- (d) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- [(e)] the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);
- (f) — the full length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or
- (g) — the full length coding sequence of the cDNA deposited under ATCC accession number 209905

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

63. (currently amended) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 shown in Figure 142 (SEQ ID NO:352);
- (b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- (c) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352);
- (d) — a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;
- [(e)] (c) the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351);
- [(f)] (d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351); or
- [(g)] (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905.

64. (currently amended) The isolated nucleic acid of Claim 63 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 shown in Figure 142 (SEQ ID NO:352).

65. (currently amended) The isolated nucleic acid of Claim 63 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide.

66. (canceled)

67. (canceled)

68. (currently amended) The isolated nucleic acid of Claim 63 comprising the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351).

69. (currently amended) The isolated nucleic acid of Claim 63 comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:351 shown in Figure 141 (SEQ ID NO:351).

70. (previously presented) The isolated nucleic acid of Claim 63 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209905.

71. (canceled)

72. (canceled)

73. (canceled)

74. (previously presented) A vector comprising the nucleic acid of Claim 58 or 63.

75. (previously presented) The vector of Claim 74, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

76. (previously presented) A host cell comprising the vector of Claim 74.
77. (previously presented) The host cell of Claim 76, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.